Skip to main content
Clinical Trials/NCT00508378
NCT00508378
Completed
Not Applicable

Chemotherapy-Related Toxicities In Ovarian Cancer Patients: Preference Assessments of Patients, Family Members, Ancillary Staff and Gynecologic Oncologists, and Patients' Quality of Life

M.D. Anderson Cancer Center1 site in 1 country288 target enrollmentJanuary 2001
ConditionsOvarian Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ovarian Cancer
Sponsor
M.D. Anderson Cancer Center
Enrollment
288
Locations
1
Primary Endpoint
Qualitative information on how ovarian cancer patients, their family members, and doctors and nurses feel about the side-effects of chemotherapy.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Primary Objectives:

  1. To assess the preferences of women with ovarian cancer, their clinical caregivers, familial caregivers, and a control group for toxicities associated with chemotherapy.

    • To compare preferences of women with ovarian cancer to preferences of their clinical caregivers.
    • To compare preferences of women with ovarian cancer to preferences of their familial caregivers.
    • To compare preferences of women with ovarian cancer to preferences of a women in the control group.
  2. To prospectively collect quality of life data from women with ovarian cancer.

  3. To prospectively collect symptom assessment data from women with ovarian cancer.

Detailed Description

Patients in this study will be recruited from the Gynecologic Oncology Clinic waiting area. All participants (patients, family and clinical caregivers, control group women with no cancer) in this study will take part in an interview to see how they feel about the different side-effects of chemotherapy. The interview will involve reading short descriptions of the side-effects and then answering some questions that ask for an opinion. The actual interview will take about 30-45 minutes to complete. The interviews will either take place in private conference rooms in the clinic or in private rooms at the Ambulatory Treatment Center (ATC). Patients will also be given quality of life and symptom assessment questionnaires. The questionnaires are simple to read and quick to answer. The questionnaire takes about 15 minutes to complete. The participant's involvement in this study is limited to the questionnaire/interview. Once that is done, the participant is finished with the study. This is an investigational study. A total of 288 people will take part in this study. All will be enrolled at M. D. Anderson.

Registry
clinicaltrials.gov
Start Date
January 2001
End Date
November 3, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Women with epithelial ovarian cancer presenting to the UTMDACC Gynecologic Oncology Clinic who are currently undergoing chemotherapy
  • Women with a history of epithelial ovarian cancer presenting to the UTMDACC Gynecologic Oncology Clinic who are seen in follow-up
  • Women who are at least 18 years of age
  • Women who speak English
  • Clinical caregivers of patients with ovarian cancer (UTMDACC gynecologic oncologists, UTMDACC gynecologic medical oncologists, UTMDACC registered nurses and licensed vocational nurses in the UTMDACC Gynecology Clinic, and UTMDACC gynecologic oncology fellows and residents)
  • Familial caregivers of patients with ovarian cancer (primary caregiver)

Exclusion Criteria

  • Participants who are non-English speakers
  • Participants who are less than 18 years of age

Outcomes

Primary Outcomes

Qualitative information on how ovarian cancer patients, their family members, and doctors and nurses feel about the side-effects of chemotherapy.

Time Frame: 8 Years

Secondary Outcomes

  • Patient Response to Quality of Life Using Interview + Questionnaire(30 minute interviews + 15 minutes for questionnaire)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Search for Predictors of Therapeutic Response in Ovarian CarcinomaCarcinoma of the OvaryFallopian Tube CancerPeritoneal Serous-type Advanced Stage
NCT01391351Centre Francois Baclesse107
Unknown
Not Applicable
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerStage I Ovarian Cancer AJCC v6 and v7Stage IA Fallopian Tube Cancer AJCC v6 and v7Stage IB Fallopian Tube Cancer AJCC v6 and v7Stage IC Fallopian Tube Cancer AJCC v6 and v7Stage II Ovarian Cancer AJCC v6 and v7Stage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7
NCT01366183Gynecologic Oncology Group290
Withdrawn
Not Applicable
Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian CancerOvarian Cancer
NCT01606358Rennes University Hospital
Unknown
Not Applicable
Retrospective Study of Ovarian Cancer Patients With Brain MetastasisOvarian CancerBrain Metastases
NCT01258881National Taiwan University Hospital70
Active, not recruiting
Not Applicable
Ovarian Reserve After Cancer: Longitudinal EffectsEffects of ChemotherapyPremature Ovarian Failure
NCT02467231University of Pennsylvania196